Paper Details

  1. Home
  2. Paper Details

HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.

Author: ChimukangaraBenjamin, GordonMichelle, MbheleNokuzola

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Integrase strand transfer inhibitors (INSTIs) are becoming increasingly popular for the treatment of HIV-1 infection. This review discusses the development of INSTIs, their mechanism of action, and the five INSTIs approved by the FDA: dolutegravir (DTG), raltegravir (RAL), elvitegravir (EVG), bictegravir (BIC), and cabotegravir (CAB). The review also highlights the genetic barrier to resistance and the side effects associated with each INSTI.
Paper Details　
Original Abstract of the Article :
Antiretroviral therapy has been imperative in controlling the human immunodeficiency virus (HIV) epidemic. Most low- and middle-income countries have used nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors extensively...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijantimicag.2021.106343

データ提供：米国国立医学図書館（NLM）

HIV-1 Integrase Strand Transfer Inhibitors: A Journey of Innovation and Discovery

The fight against HIV-1 infection is a continuous journey of discovery and innovation. This review, published in the journal Viruses, explores the development and use of integrase strand transfer inhibitors (INSTIs), a class of drugs that have revolutionized HIV-1 treatment.

The authors, like intrepid explorers charting a new territory in the desert of viral infections, discuss the evolution of INSTIs, highlighting their effectiveness in halting HIV-1 replication. They examine the five FDA-approved INSTIs: dolutegravir, raltegravir, elvitegravir, bictegravir, and cabotegravir. These drugs represent significant advancements in HIV-1 treatment, offering a new oasis in the desert of viral infections.

A New Era of Treatment: Navigating the Desert of HIV-1 Infection

The development of INSTIs has transformed HIV-1 treatment, offering a new era of hope for individuals living with the virus. This review provides a comprehensive overview of these drugs, their mechanisms of action, and their potential benefits. It’s like discovering a new and promising route through a challenging desert environment, offering a path toward a healthier future.

Managing HIV-1 Infection: A Journey of Awareness and Proactive Care

Individuals at risk of HIV-1 infection should practice safe sex, get tested regularly, and access appropriate medical care. Just as a wise desert traveler prepares for their journey, individuals should take proactive steps to protect their health and seek guidance from healthcare professionals. The ongoing research and development of new treatments offer hope for a future where HIV-1 infection is effectively managed and controlled.

Dr. Camel's Conclusion

This review highlights the significant progress made in HIV-1 treatment with the development of integrase strand transfer inhibitors (INSTIs). These drugs, like oases in the desert of viral infections, offer a new era of hope for individuals living with HIV-1, leading to a healthier and more fulfilling journey.

Date :
  1. Date Completed 2021-10-18
  2. Date Revised 2021-10-18
Further Info :

Pubmed ID

33852932

DOI: Digital Object Identifier

10.1016/j.ijantimicag.2021.106343

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.